We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Raloxifene Prevails in STAR Trial, May Face Easier Road to Acceptance Than Previous Drugs.
- Authors
Vastag, Brian
- Abstract
The article reports on the study designed to compare the effectiveness of tamoxifen and raloxifene to prevent breast cancer in the U.S. Larry Wickerham, associate director of the National Surgical Adjuvant Breast and Bowel Project, announced that the winner in the study is raloxifene. The result have prompted raloxifene maker Eli Lilly & Co. to petition the Food and Drug Administration for permission to market raloxifene for breast cancer prevention.
- Subjects
UNITED States; RALOXIFENE; TAMOXIFEN; WICKERHAM, Larry; BREAST cancer; ELI Lilly &; Co.; UNITED States. Food &; Drug Administration; CANCER prevention
- Publication
JNCI: Journal of the National Cancer Institute, 2006, Vol 98, Issue 11, p733
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djj253